| Identification | Back Directory | [Name]
3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester | [CAS]
2759351-68-1 | [Synonyms]
3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester | [Molecular Formula]
C51H56FN9O10S | [MOL File]
2759351-68-1.mol | [Molecular Weight]
1006.11 |
| Hazard Information | Back Directory | [Uses]
Dovitinib RIBOTAC is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC can inhibit the metastasis of breast cancer and has anti-tumor activity[1]. | [in vivo]
Dovitinib RIBOTAC (56 mg/kg; intraperitoneal injection; every other day; 30 days) exhibits anti-tumor activity in a xenograft mouse model of breast cancer[1].
Dovitinib RIBOTAC (56 mg/kg; intraperitoneal injection; every other day; 42 days) has an ameliorative effect in a mouse model of Alport Syndrome. It can stabilize the urine albumin concentration, reduce the levels of mature and precursor miR-21 in the kidneys, and increase the PPARα protein level[1]. | Animal Model: | MDA-MB-231-Luc cells treated female NOD/SCID mice[1] | | Dosage: | 56 mg/kg | | Administration: | Intraperitoneal injection; every other day; 30 days | | Result: | Inhibited breast cancer metastasis.
Decreased the number of lung nodules.
Significantly diminished miR-21 and pre-miR-21 expression.
Derepressed PDCD4 expression while having no effect on ERK or pERK levels.
|
| [References]
[1] Zhang P, et al. Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment. J Am Chem Soc. 2021 Aug 25;143(33):13044-13055. DOI:10.1021/jacs.1c02248 |
|
|